Evidence map›Paper›PMID 27559494›Full record

ArticleExpert opinion on orphan drugs

Novel Therapeutic Strategies for the Management of Ventricular Arrhythmias Associated with the Brugada Syndrome.

Bence Patocskai, Charles Antzelevitch

Open access · greenAbstract read
In one paragraph

Article in Expert opinion on orphan drugs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 21 citations in OpenAlex.

  1. Identification of Lauric Acid as a Potent Sodium Channel NaDrug design, development and therapy · 2025
    Article
  2. Article
  3. Inter-Regulation of KInternational journal of molecular sciences · 2020
    Article
  4. Recent advances in the treatment of Brugada syndrome.Expert review of cardiovascular therapy · 2018
    Review
  5. Pharmacological Therapy in Brugada Syndrome.Arrhythmia & electrophysiology review · 2018
    Review
  6. Article
  7. J-Wave syndromes expert consensus conference report: Emerging concepts and gaps in knowledge.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2017
    Review
  8. Pathogenesis and management of Brugada syndrome.Nature reviews. Cardiology · 2016
    Review
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Bence PatocskaiDepartment of Pharmacology & Pharmacotherapy, University of Szeged, Szeged, Hungary.
Charles AntzelevitchSUNY Upstate Medical University, Syracuse, NY 13210.
SUNY Upstate Medical University · USUniversity of Szeged · HU

Funding

ELECTRICAL HETEROGENEITY AND CARDIAC ARRHYTHMIASR01HL047678 · NHLBI · MASONIC MEDICAL RESEARCH LABORATORY, INC · PI ANTZELEVITCH, CHARLES · 1993 to 2014
$5.7M
NHLBI NIH HHS R01 HL047678
6 · The paper itself

Abstract

introductionBrugada syndrome (BrS) is an inherited cardiac arrhythmia syndrome characterized by prominent J waves appearing as distinct coved type ST segment elevation in the right precordial leads of the ECG. It is associated with a high risk for sudden cardiac death. AREAS COVERED: We discuss 1) ECG manifestations of BrS which can be unmasked or aggravated by sodium channel blockers, febrile states, vagotonic agents, as well as tricyclic and tetracyclic antidepressants; 2) Genetic basis of BrS; 3) Ionic and cellular mechanisms underlying BrS; 4) Therapy involving devices including an implantable cardioverter defibrillator (ICD); 5) Therapy involving radiofrequency ablation; and 6) Therapy involving pharmacological therapy which is aimed at producing an inward shift in the balance of the currents active during phase 1 of the right ventricular action potential either by boosting calcium channel current (isoproterenol, cilostazol and milrinone) or by inhibition of transient outward current I EXPERT OPINION: This review provides an overview of the clinical and molecular aspects of BrS with a focus on approaches to therapy. Available data suggest that agents capable of inhibiting the transient outward current I

Identifiers

PMID27559494
PMCPMC4993532
OpenAlexW2099668379

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.